We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants

By LabMedica International staff writers
Posted on 25 May 2021
Print article
Image: Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants (Photo courtesy of Seegene, Inc.)
Image: Seegene Unveils Exclusive Diagnostic System for Diagnosing COVID-19 Variants (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, Korea) has introduced a unique system for diagnosing COVID-19 variants at the European Congress of Clinical Microbiology (ECCMID) 2021.

Seegene's Dr. Guy Willem Lee, Director of Marketing Strategy introduced the diagnostic system at ECCMID 2021under the theme of "SARS-CoV-2 and Variants 'Full Screening' Solution" using its latest COVID-19 variant diagnostic tests. The 'Full Screening Solution' is a one-step system that can verify whether an individual has contracted coronavirus wildtype or the virus variant with a single real-time PCR test. Currently, health authorities are forced to go through an extra round of genomic sequencing to distinguish the existence of COVID-19 variants after standard PCR tests, automatically leading to a more prolonged testing time.

Against the backdrop of Seegene's 'Full Screening Solution' are the company's latest variant diagnostic tests, the Allplex SARS-CoV-2 Master Assay and Allplex SARS-CoV-2 Variants I Assay. The Allplex SARS-CoV-2 Master is an ideal way of screening for the COVID-19, as it provides results of whether a person is positive of the COVID-19 or even its variants. After an initial round of testing, Seegene's Allplex SARS-CoV-2 Variants I Assay will help identify multiple mutant variations in a single reaction.

The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes (E gene, RdRP gene, N gene and S gene) as well as five defined virus variants notably spotted in the most recognized lineages including B1.1.7, B.1.351, P.1 and B.1.1.207. Seegene's variant diagnostic test is the first such kind to simultaneously detect multiple coronavirus genes and differentiate virus variations, including those found to be more contagious and fatal. It is an ideal and economic way of screening coronavirus genes as the pandemic continues to rage with both the wildtype and its virus variants.

Lee proposed that the system would play a critical role in controlling the spread of COVID-19 pandemic amid fast spreading virus variants.

“The backdrop of Korea's outstanding control at the onset of the pandemic is because of the one-platform diagnostic system that enables mass testing," said Lee. He added that “the system enabled the diagnostic process from sample collection through PCR testing all at once, helping local authorities to quickly control the pandemic.”

"A swift diagnostic system is extremely critical in helping to control the resurgence of the COVID-19 pandemic," added Dr. Nakmoon Sung of Seegene Medical Foundation. "The one-step and accurate diagnostics will become the global standard in detecting coronavirus and other respiratory diseases, for the purpose of accurate treatment".


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.